Nosocomial Infection Treatment Market: Introduction

• Nosocomial infection is termed as infection caused within 48 hours of hospital admission. Hence, it is also known as hospital-acquired infection. Patients in intensive care units (ICU) are more prone to hospital-acquired infections.
• About 90% hospital-acquired infections are bacterial infections.  coli, P. aeruginosa, and S. aureus are the most common bacteria responsible for urinary and respiratory tract infections, wound, kidney, and blood infection. Excessive and misuse of antibiotics has led to increase in number of nosocomial infections.

Report Overview:

https://www.transparencymarketresearch.com/nosocomial-infection-tre...

Key Drivers and Opportunities of Global Nosocomial Infection Treatment Market

• Increase in incidence of hospital-acquired infections is projected to boost the growth of the global nosocomial infection treatment market. According to the Centers for Disease Control and Prevention, an estimated 1.7 million infections and 99,000 deaths occur due to healthcare-acquired infections in hospitals in the U.S. each year.
• Moreover, rise in prevalence of nosocomial infections such as urinary tract infection, tuberculosis, surgical wound infection, and respiratory tract infection is anticipated to fuel the growth of the global market. According to the Pharmacotherapy Self-Assessment Program: Hematology/Oncology, approximately 60% of women have symptomatic UTI during their lifetime and in the U.S., around 10% women have one or more than one UTI episodes each year. According to the World Health Organization, globally, an estimated 10 million people fell ill with tuberculosis in 2018. According to the Centers for Disease Control and Prevention, around 157,500 surgical site infections are reported in the U.S. each year.
• Antibiotics are the most commonly prescribed treatments for nosocomial infections. Excessive use of antibiotics leads to microbial antibiotic resistance. Hence, development of new antibiotics is underway in order to overcome multiple drug resistance. For instance, in July 2019, the U.S. Food and Drug Administration approved the antibacterial drug, Recarbrio, for the treatment of complicated UTIs and complicated intra-abdominal infection in adults.
• In February 2018, Allergan received the U.S. Food and Drug Administration approval for New Drug Application of Avycaz. The drug was approved for the treatment of patients with ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
• Increase in demand for new antibiotics for effective therapy presents considerable opportunity to manufacturers in the market
• Rise in prevalence of nosocomial infections in developing countries creates lucrative opportunities in the global market. According to the Second Australian Atlas of Healthcare Variation, an estimated 73,777 hospitalizations for kidney and urinary tract infections were reported in Australia in 2014–2015.

North America to Capture Major Share of Global Nosocomial Infection Treatment Market

• North America is expected to account for major share of the global nosocomial infection treatment market during the forecast period due to presence of key players and product launch & approvals. Moreover, rise in prevalence of nosocomial infections is likely to fuel the growth of the market in the region. According to the American Urology Association, the estimated incidence of UTI is 0.5 to 0.7 per person per year in premenopausal women in the U.S.
• The nosocomial infection treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to increase in awareness and surge in geriatric population.

Request For Custom Research:

https://www.transparencymarketresearch.com/sample/sample.php?flag=C...

Key Players Operating in Global Nosocomial Infection Treatment Market

The global nosocomial infection treatment market is highly consolidated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Growth strategies adopted by key players are likely fuel the growth of the global market. For instance, in July 2018, Nabriva Therapeutics plc acquired Zavante Therapeutics. This acquisition enabled the company to strengthen its leading positioning and develop new anti-infectives.

Major players operating in the global nosocomial infection treatment market are:

• Allergan
• Pfizer, Inc.
• Bayer AG
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Almirall, S.A.
• Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
• Reddy’s Laboratories Ltd.
• Lupin Pharmaceuticals, Inc.
• Johnson & Johnson's (Janssen Global Services, LLC)

Global Nosocomial Infection Treatment Market: Research Scope

Global Nosocomial Infection Treatment Market, by Drug Class

• Beta-lactams
• Quinolones
• Aminoglycosides
• Others

Global Nosocomial Infection Treatment Market, by Type of Infection

• Ventilator-associated Pneumonia
• Tuberculosis
• Urinary Tract Infection
• Legionnaires’ Disease
• Surgical Wound Infection
• Lower Respiratory Tract Infection
• Surgical Site Infections
• Others

Global Nosocomial Infection Treatment Market, by Infectious Agent

• Bacteria
• Fungus
• Viruses

Global Nosocomial Infection Treatment Market, by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Nosocomial Infection Treatment Market, by Region

• North America
  • S.
  • Canada
• Europe
  • Germany
  • France
  • K.
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Pre Book:

https://www.transparencymarketresearch.com/checkout.php?rep_id=7583...

About Us 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial! 

Contact Us 

Mr. Rohit Bhisey 
Transparency Market Research, 
90 State Street, Suite 700, 
Albany, NY 12207 
Tel: +1-518-618-1030 
USA – Canada Toll Free: 866-552-3453 
Email: [email protected] 
Website: https://www.transparencymarketresearch.com/